Banner Image Banner Image

Investors
& Media

Press Releases

Press Releases

All Releases
TG Therapeutics Announces Proposed Public Offering of Common Stock
NEW YORK , May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases (“TG Therapeutics”), today announced that it intends to offer and sell 6,000,000 shares of its common stock in
May 14, 2020
TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings
NEW YORK , May 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 56 th American Society of Clinical Oncology (ASCO) annual meeting, to be held virtually May 29 – June 1, 2020 and the 25 th European Hematology
May 14, 2020
TG Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results
NEW YORK , May 11, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ended March 31, 2020 and recent company developments. Michael S. Weiss , the Company's Executive Chairman and Chief Executive Officer, stated, “The first few
May 11, 2020
TG Therapeutics Strengthens Executive Team with the Addition of Owen A. O’Connor, MD, PhD, as Chief Scientific Officer
NEW YORK , May 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Owen A. O’Connor, MD, PhD, has joined the Company as Chief Scientific Officer. Dr. O’Connor brings extensive scientific experience in developing drug candidates in oncology and hematology, and
May 08, 2020
TG Therapeutics Raises Approximately $60 Million in Gross Proceeds Through its At-the-Market Facility
$40 million of which came from longtime shareholder, RA Capital Management NEW YORK , May 06, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it has raised gross proceeds of approximately $60 million through its At-the-Market (ATM) facility, $40 million of which came
May 06, 2020
TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia
UNITY-CLL trial met the primary endpoint of improved progression-free survival (PFS) (p<.0001 and="" will="" be="" stopped="" early="" for="" superior="" efficacy="" observed="" at="" the="" interim="" analysis="" pfs="" benefit="" seen="" across="" both="" previously="" untreated="" relapsed="" patient="" populations="" regulatory="" submission="">
May 05, 2020
TG Therapeutics Announces Publication of Ublituximab Phase 2 Clinical Trial Results in Multiple Sclerosis Journal
Ublituximab was generally well tolerated across all cohorts including those patients receiving one-hour infusions for the 450mg dose currently being studied in the Phase 3 ULTIMATE MS program Annualized Relapse Rate of 0.07 observed at week 48 NEW YORK , May 01, 2020 (GLOBE NEWSWIRE) -- TG
May 01, 2020
TG Therapeutics Bolsters Board of Directors with the Appointment of Sagar Lonial, MD
NEW YORK , April 29, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the appointment of Sagar Lonial , MD, FACP, to the Company’s Board of Directors. Dr. Lonial has extensive experience in multiple myeloma and lymphoma treatment and research, and most recently has
Apr 29, 2020
TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting
NEW YORK , March 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX), today announced that abstracts featuring ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS), have been selected for presentation at the
Mar 09, 2020
TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Follicular Lymphoma
NEW YORK , March 05, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to umbralisib, the Company’s investigational dual inhibitor of PI3K-delta and CK1-epsilon, for the treatment of
Mar 05, 2020
Displaying 11 - 20 of 24